to increase granularity by subclassifying CKD into more specific forms 10 , such as diabetic nephropathy or immune-mediated glomerulonephritis. Indeed, the KDIGO guidelines 11 recommend identification of the specific underlying disease where possible. The issue of disease heterogeneity represents a major hurdle to the management of patients with CKD and affects definitions of disease prevalence but this topic is beyond the scope of this Review.
Diagnosing CKD
The reported prevalence of CKD in epidemiological studies varies depending on the clinical characteristics of the population analysed and the approach used to define and diagnose CKD [1] [2] [3] [4] [5] [6] [7] 12, 13 . The way in which GFR is assessed has a considerable effect on our understanding of CKD epidemiology. Ideally, GFR should be measured. Measured (m)GFR gives an accurate assessment of kidney function and avoids confounding by interactions with variables, such as age or weight, that are included in some eGFR equations. Further, non-GFR determinants can affect eGFR values that are derived from equations based on serum creatinine or cystatin C. For example, muscle wasting or increased muscle mass can alter creatinine levels, and inflammation and/or obesity can alter the levels of cystatin C [14] [15] [16] .
Measuring GFR
The gold-standard approach to measure GFR involves measurement of inulin urinary clearance 17 
however, this approach is too costly and cumbersome for use in large epidemiologic studies (in our estimation those with >10,000 participants). For inulin, measurement of urinary clearances with intravenous continuous infusion (after a loading dose) are required. Two or three urine collections of 30-60 min are necessary after reaching a period of equilibrium around 60 min. The rate of plasma clearance of iodinated contrast agents, such as iohexol and iothalamate, has also been used to measure GFR without urine collections in small-to-medium sized cohort studies and clinical trials. This approach, however, has its own unique drawbacks, such as a requirement for repetitive plasma samples over many hours, and is not well suited to very large epidemiological studies of CKD prevalence because of cost and inconvenience. Use of iodinated contrast plasma clearance to assess GFR in some observational studies (with up to ~1,600 participants) might, however, inform the interpretation of larger epidemiology studies that have relied on eGFR. For example, the observational Chronic Renal Insufficiency Cohort (CRIC; n = 1214) study, the Berlin Initiative Study (BIS; n = 570), the Age, Gene/Environment Susceptibility study (n = 805) and the Renal Iohexol Clearance Survey (RENIS; n = 1,632), assessed plasma clearance of iothalamate (CRIC) or iohexol (BIS, the Age, Gene/Environment Susceptibility study, and RENIS) and could be used as reference studies for larger investigations [18] [19] [20] [21] [22] . Despite the associated costs and complexity of approaches to measure GFR, these approaches provide a more accurate description of renal function than the currently available equations for GFR estimation, and have the potential to improve our understanding the epidemiology of CKD. The RENIS and BIS are interesting examples of how the reported prevalence of CKD can differ according to the method used to assess GFR. The RENIS used a single sample of iohexol clearance to assess mGFR among individuals aged 50-62 years with a low risk of cardiovascular disease drawn from the general population in Tromsø, Norway 20, 23 . The prevalence of CKD (defined as GFR <60 ml/min/1.73 m² according to iohexol clearance)
Key points
• Chronic kidney disease (CKD) is presently defined by a matrix of biomarkers, specifically, glomerular filtration rate (GFR) <60 ml/min/1.73 m 2 and albuminuria in the context of manifestations of kidney damage and duration >3 months • GFR can be measured or estimated but both of these approaches to assess kidney function have drawbacks when applied to epidemiologic studies of the population prevalence of CKD • Failure to apply the >3 month duration requirement for CKD diagnosis can lead to an overestimation of CKD prevalence, especially when age, sex, ethnicity and diet are not taken into account • Data from multiple sources indicate that CKD is a common disorder that contributes markedly to morbidity and mortality; however, the prevalence of CKD shows wide variations between and within specific geographic locations • In many nations, including the USA, the prevalence of CKD and newly treated end-stage renal disease (ESRD) is stable; future trends in ESRD prevalence will likely depend on changes in access to treatment, population demographics and mortality
Box 1 | Approaches to measuring GFR
Measured glomerular filtration rate (mGFR) requires an exogenous marker with specific physiological characteristics: free in plasma (not bound to proteins), freely and fully filtrated through the glomerulus, neither secreted nor absorbed by tubules, inert, safe, only excreted by the kidneys and fairly easy to measure in plasma and/or urine. Urinary clearance of inulin was first described by pioneers in nephrology in the thirties [96] [97] [98] and is still considered to be the gold standard method for GFR measurement. As renal clearance of inulin is relatively cumbersome (please see the text for further details), some authors have proposed alternatives such as isotopic ( 51 Cr-EDTA, 99 Tc DTPA and 125 I-iothalamate) or non-isotopic methods (iohexol and iothalamate). Contrary to inulin that can only be used with urinary clearance, the proposed markers can be used in plasma clearance protocols. Plasma clearances are less physiologic and inaccurate in patients with cirrhosis or oedema, but are easier to implement in daily practice or in specific populations such as paediatric or geriatric patients. Different procedures of plasma clearances (number of samples and timing) have been described in the literature 98, 99 . Each marker and each procedure has strengths and limitations. Even with a lack of standardization between mGFR procedures and markers, data suggest that urinary clearance of 51 Cr-EDTA and iothalamate or plasma clearance of 51 Cr-EDTA and iohexol are acceptable alternatives to urinary clearance of inulin 98 .
Jaffe assays
Used for measuring serum creatinine levels. Jaffe assays are based on a colourimetric reaction using alkaline picrate; the colour change is directly proportional to the creatinine concentration. Unfortunately, the accuracy of the assay can be affected by interfering factors such as haemolysis, hyperbilirubinemia, lipaemia and non-creatinine chromogens such as glucose, acetoacetate and ascorbic acid.
was extremely low (2.12%), but the ability of two eGFR equations (The Modification of Diet in Renal Disease (MDRD) study equation and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; BOX 2) to detect a mGFR <60 ml/min/1.73 m² was extremely poor (100% specificity and only 18% sensitivity with an area under the receiving operating characteristic curve of 0.76 for both equations) 20 . BIS also used iohexol clearance to assess GFR in a European cohort of elderly patients (mean age 79 years) 7, 21 . The prevalence of CKD (defined as GFR <60 ml/min/1.73 m²) was notably higher when assessed by plasma iohexol clearance than by creatinine-based eGFR equations, such as the MDRD or CKD-EPI equations. Indeed in the 570 individuals with GFR measured by iohexol plasma clearance, prevalence of GFR <60 ml/ min/1.73 m² was 47.9%, 27.7% and 30.2% with iohexol, MDRD and CKD-EPI, respectively 21 (TABLES 1,2).
As described above, estimates of CKD prevalence are dependent on the approach used to assess GFR. In our view, measuring GFR using inulin, iohexol or iothalamate clearance will result in a more accurate understanding of the prevalence of CKD. Although the current number of observational studies that have utilized plasma disappearance or urinary clearance methods to assess mGFR is still too low to be conclusive, we expect the prevalence of CKD to differ according to whether GFR is measured or estimated. Moreover, the difference between eGFR and mGFR could vary according to the age of the study population, the choice of eGFR equation and the biomarkers utilized.
The limitations of biomarkers
The two most commonly used biomarkers for assessing eGFR in clinical practice are serum creatinine and plasma cystatin C
. These biomarkers present three potential issues that need to be considered in the context of epidemiological studies: the calibration of biomarker assays to ensure inter-laboratory consistency; interference by non-GFR determinants; and day-to-day biological variations in biomarker concentrations.
Assay calibration issues. The calibration of biomarker assays is fundamental to the study of CKD prevalence in the general population. The reported level of serum creatinine in any given sample can vary depending on the assay used for analysis; for example, differences have been reported when analysing the same sample from a single patient using two different creatinine assays 24, 25 . Although differences in measured serum creatinine levels from a single patient could be considered negligible, investigators must bear in mind that assay readouts are used in eGFR equations and that these equations apply an exponent to the serum creatinine value 24 . An example of how variations in serum creatinine assay calibration can affect eGFR readouts is illustrated by a study in which investigators measured the serum creatinine levels of non-diabetic patients from the National Health and Nutrition Examination Survey III (NHANES III) using two different Jaffe assays
25 .
The reported serum creatinine concentrations from the two assays differed by 20.3 µmol/l (0.23 mg/dl). Variations of this size between readouts have a huge impact on eGFR calculations and CKD staging using equations such as MDRD. In this study, for example, the prevalence of eGFRs of 30-59 ml/min/1.73 m² varied from 3.2% to 12.5% due solely to differences in the method used to measure serum creatinine level. Moreover, as the relationship between serum creatinine level and GFR is exponential, the impact of differences in serum creatinine levels on GFR estimates is even more pronounced in higher GFR ranges (>80 ml/min/1.73 m 2 ). The reported prevalence of GFR >80 ml/min/1.73 m² varied in the same study from 41.8% to 82.1% 25 . . More recent equations have the advantage of being isotope dilution mass spectrometry (IDMS) traceable (discussed further in the text) and perform better than the C-G equation at estimating GFR 52, 100 . The first IDMS traceable equation was the Modification of Diet in Renal Disease (MDRD) study equation 101 , now replaced by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which has slightly better performance in high GFR ranges 29 . Other equations have been proposed: the BIS equation 21 , specifically proposed for estimating GFR in elderly populations, the Lund-Malmö equation 31 and the full age spectrum (FAS) equation 30 . The FAS equation is particularly original in its development but, as with the Lund-Malmö equation, it still needs to be externally validated. Among cystatin C and combined (creatinine and cystatin C) equations, different equations developed from a standardized cystatin C are currently available (CKD-EPI, Lund-Malmö, BIS and Caucasian, Asian, pediatric, and adult (CAPA) equations) 21, 31, 74, 102 .
IDMS traceable
A serum creatinine value that has been obtained using an assay that has been calibrated to single standardized serum creatinine using reference materials traceable to the primary reference material at the National Institute of Standards. The value is described as being traceable to isotope dilution mass spectrometry (IDMS) because the assay calibration is based on IDMS.
According to these findings, intra-individual variations in eGFR calculations that result from shortfalls in assay calibration could be reduced if each eGFR equation was used solely with the specific assay it was developed alongside 24, 25 ; however, this approach can be problematic as newer assays are developed over time and replace older ones. For instance, the creatinine assay on which the Cockcroft-Gault (C-G) equation for estimated serum creatinine clearance was based is no longer in use 26 . Application of modern assays for serum creatinine concentration to the C-G equation could lead to potential errors because the original formulation of the C-G equation was derived from obsolete creatinine-based methodology and the equation has never been validated using contemporary methods.
Over the past decade clinical chemists have made considerable advances in standardizing assays for serum creatinine 27 . Manufacturers are recommended to calibrate their serum creatinine assays to an isotope dilution mass spectrometry (IDMS) reference method, making the assay IDMS traceable 28 . A major advantage of using IDMS traceable assays is that an eGFR equation developed with one IDMS traceable assay can be used with any other IDMS traceable assay 21, 27, [29] [30] [31] . The introduction of IDMS calibration for serum creatinine assays has gone some way to address the variability of serum creatinine readouts but issues remain with regard to using eGFR to assess CKD prevalence in epidemiological studies. A continuing complication is that the effect of assay calibration differs between eGFR equations. Variations in calibration have a greater effect on the MDRD equation, for example, than on the CKD-EPI equation for eGFR. The reason for the different effect of variations in calibration between the two eGFR equations is that the mathematical exponent that is applied to serum creatinine in high GFR ranges is lower in the CKD-EPI than in the MDRD equation 32, 33 . Although some studies have used IDMS traceable assays to measure serum creatinine, others have not directly calibrated serum creatinine to a mass spectrometry standard but rather have indirectly recalculated serum creatinine levels by comparing assays to other IDMS traceable assays 34, 35 . Furthermore, not all investigators agree that the accuracy of IDMS calibration is sufficient. Some have questioned the calibration of some assays, especially Jaffe assays, even following manufacturer assurances that the assay was correctly calibrated 36 . We would argue, however, that most enzymatic assays for creatinine are well calibrated 28, 36 . Cystatin C assays and associated equations can also be affected by calibration issues 37, 38 . Difficulties in measuring cystatin C by mass spectrometry have hindered the development of a reliable mass spectroscopy reference standard 39 , but assay standardization has improved since 2010 when the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) made the international certified reference material ERM-DA471/ IFCC for cystatin C assay calibration available to all assay manufactures 40 . A 2016 publication reported major progress in the standardization of cystatin C assays 41 ; however a 2015 study reported substantial method-specific differences in cystatin C measurements 42 .
Non-GFR determinants. The second issue with every biomarker used to estimate GFR is the modifying effect of non-GFR determinants and non-GFR-related factors on biomarker levels (FIG. 1) . The classic example is muscle mass, which influences serum creatinine level. Thus, creatinine-based equations (such as the MDRD and CKD-EPI equations) can provide inaccurate estimates of true GFR when marked variation of muscle mass (too much or too little) is present 21, 43 . Cystatin C is not influenced by muscle mass but can be influenced by other non-GFR determinants. Many of these factors, such as obesity, chronic inflammation, diabetes mellitus, smoking and abnormalities of thyroid function (hypothyroidism or hyperthyroidism), are also cardiovascular risk factors, and contribute to the association between cystatin C levels and cardiovascular risk 8, 14, 16, [44] [45] [46] . The choice of an appropriate eGFR equation is therefore imperative when assessing the influence of potential risk factors on CKD prevalence. Assessment of the Box 3 | Jaffe versus enzymatic methods for measuring biomarkers Serum creatinine remains the main variable in all proposed equations for estimating glomerular filtration rate. Measuring creatinine level in serum is cheap but not simple. The original and still most used approach is the Jaffe method. This colourimetric method is based on the reaction between creatinine and picric acid, which gives a yellow-red colour to serum that can be quantified. However, other components in plasma, known as pseudochromogens, can also react and/or interfere with picric acid (acetone, glucose, acetoacetate, proteins, ascorbate and glucose). This lack of specificity can lead to abnormal high values (~17.6-26.5 μmol/l (0.2-0.3 mg/dl) higer than other assays). Although several improvements have been made, the precision of the Jaffe method remains fairly limited, impacting the precision of the equations. Enzymatic methods for measuring biomarker concentrations are based on successive and different (assay-dependent) enzymatic reactions. These methods are much more precise than the Jaffe method, notably because their specificities regarding pseudochromogens and other interferences are much higher. The errors or imprecision associated with Jaffe assays particularly affects low creatinine concentrations. For this reason, enzymatic creatinine methods are recommended in paediatric patients 32, 103, 104 . influence of obesity on the risk of CKD, for example, would be poorly served by an eGFR equation that is based on a biomarker, such as cystatin C, which is influenced by non-GFR determinants related to obesity. Non-GFR determinants, therefore, have an undeniable and varying effect on estimates of CKD prevalence and assessment of CKD risk in populations with diverse characteristics.
Biological variations. Serum creatinine concentrations can fluctuate regularly under the influence of factors such as dietary intake of cooked red meat or other precursors of creatinine and diurnal rhythms. Non-GFR determinants that vary naturally throughout each day, such as food (especially meat) intake, or consumption of drugs (such as cimetidine and trimethoprim) that affect creatinine secretion by tubules, can affect serum creatinine levels. These factors can also be an important source of eGFR miscalculation, particularly if only a single serum creatinine measurement is used to define the presence or absence of CKD. Similar to GFR, circadian variation has been described for cystatin C . Although data are fairly limited, cystatin C concentration does not seem to be influenced by food intake 47 . The importance of multiple serum creatinine measurements is discussed in further detail below.
Choosing an appropriate equation
Before the introduction of the MDRD study equation in 1999 (REF. 48 ), the C-G equation was the most frequently used method to estimate creatinine clearance, but was not developed as a method to estimate GFR 26 . The C-G equation is flawed when used to assess CKD prevalence in epidemiological studies because the assay used to measure serum creatinine is not calibrated and the inclusion of patient weight in the equation leads to overestimation of creatinine clearance in obese populations 49 . The MDRD and CKD-EPI equations, which can be used with IDMS-standardized creatinine values, have improved on the C-G equation by removing weight from the calculation 29, 48 . Although the MDRD and CKD-EPI equations are designed to estimate GFR rather than endogenous creatinine clearance, their performance remains suboptimal for estimating GFR in obese populations 50, 51 . Moreover, the MDRD equation has been criticized for underestimating GFR in patients with normal or near normal GFR (60-100 ml/min/1.73 m 2 ) 24, 52 . The systematic underestimation of GFR with the MDRD equation would be expected to lead to an overestimation of CKD prevalence in epidemiological studies, and is the reason why the CKD-EPI equation has been advocated since its development in 2009 (REF. 29 ).
The main difference between the MDRD and CKD-EPI equations is how exponents of serum creatinine are applied. Unlike the MDRD equation, the CKD-EPI equation applies a lower exponent to the serum creatinine value for low recorded creatinine concentrations (<61.9 µmol/l (<0.9 mg/dl) for males and <79.6 µmol/l (<0.7 mg/dl) for females), than for higher serum creatinine values. Although, when compared to mGFR the precision and accuracy of the CKD-EPI equation only marginally outperforms the MDRD equation, making the added value of this equation at the individual patient level doubtful. The systematic bias of the CKD-EPI equation, however, is notably lower than that of other equations, which makes it more suitable than most other equations for estimating CKD prevalence in epidemiological studies.
In the external validation dataset of the seminal study that directly compared the MDRD and CKD-EPI equations, the median bias (defined as the median difference between mGFR and eGFR), was 55% lower using the CKD-EPI equation than the MDRD equation As expected, use of the CKD-EPI equation gives a lower prevalence of CKD (or decreased GFR) in general or specific population cohorts than do other equations 29, [53] [54] [55] [56] [57] [58] [59] [60] [61] . Some more recently developed equations that also use IDMS-standardized creatinine measurements have been shown to be superior to CKD-EPI for estimating GFR in the both the general and CKD population. For example, the full age spectrum (FAS) and the Lund-Malmö equations are reportedly superior to the CKD-EPI equation for estimating GFR in the general population 30, 31 , and the BIS equation is superior to the CKD-EPI equation for estimating GFR in the elderly 21 . However, the impact of the FAS, Lund-Malmö and BIS equations on the estimates of the prevalence of CKD in epidemiological studies remains to be defined in the general population 60, 61 . A 2016 report from the BIS cohort illustrates how the choice of equation for eGFR can affect the reported prevalence of CKD in an elderly population (n = 2069, mean age 80.4 ± 6.7 years). The results of the study are based on only one determination of eGFR or GFR by Nature Reviews | Nephrology Figure 1 | Non-GFR determinants that affect estimated GFR. Serum creatinine and plasma cystatin C are currently the two most used biomarkers to estimate glomerular filtration rate (GFR). However, production, and thus concentrations, of these biomarkers are also influenced by diverse GFR-independent factors. These extra-renal factors can influence the accuracy of these biomarkers for estimating GFR and/or predicting outcomes.
Regression to the mean
Regression to (or toward) the mean is the phenomenon that if the level of a variable is extreme on first measurement, it will tend to be closer to the mean on second measurement, whereas if the level is extreme on second measurement, it will tend to have been closer to the mean on first measurement.
IDMS-calibrated values of creatinine and cystatin C. The prevalence of CKD, defined as eGFR <60 ml/ min/1.73 m², varied according to the creatinine-based equation used, with a prevalence of 37.9% using the CKD-EPI equation, 37.1% using the MDRD equation, 55.9% using the C-G equation, 55.3% using the LundMalmö equation, and 61.7% using the BIS equation 7 . Such discrepancies question our understanding of CKD prevalence in the elderly, especially when GFR is only measured or estimated at the inception of a study -a scenario that raises questions about false positives due to the lack of confirmation, as discussed in further detail below. Using plasma clearance of iohexol to assess GFR, the BIS investigators also noted a high prevalence of stage 3-5 CKD (mGFR <60 ml/min/ We find the scarcity of and discrepancies within epidemiological studies that have compared the prevalence of CKD using creatinine, cystatin C or combined creatinine-cystatin C-based equations surprising and worrying. Not only are such comparative studies scarce, the findings of those that are available are discrepant 54, 56, 58, [60] [61] [62] [63] [64] . Furthermore, of the studies that have been conducted, most are methodologically flawed, especially with regard to a lack of cystatin C calibration 56, 58, 63 , although, calibration of cystatin C assays does not eliminate the discrepant results obtained using cystatin-C-based equations. For example, in a nonrepresentative cohort of 4,189 Belgian citizens aged >50 years, we demonstrated that the prevalence of GFR <60 ml/min/1.73 m² differed depending on the eGFR equation used, with a prevalence of 13% with the MDRD equation, 9.8% with the serum creatinine-based CKD-EPI (CKD-EPIcr) equation, 4.7% with the cystatin C-based CKD-EPI (CKD-EPIcys) equation, and 5% with the combined serum creatinine-cystatin C-based CKD-EPI (CKD-EPIcr-cys) equation 54 . By contrast, an analysis of the NHANES 1999-2002 cohort (n = 8,238) found the prevalence of GFR <60 ml/min/1.73 m 2 to be higher using calibrated cystatin-C-based equations than with creatinine-based equations (8.7% with CKD-EPIcys; 7.1% with CKD-EPIcr-cys; and 6.5% with CKD-EPIcr) 62 . Finally, a comparison of cystatin-C-based and combined equations in the elderly BIS cohort gave a CKD prevalence of 53.1% for the combined creatinine-cystatin-C-based BIS equation and 39.3% for the CKD-EPIcr-cys equation. By contrast, the prevalences of CKD calculated using CKDEPIcys and the Caucasian, Asian, paediatric, and adult equation (CAPA) were 42.1% and 37.4%, respectively 7 . The wide variation in CKD prevalence observed when different eGFR formulas are applied to populations of varying ages is a very real conundrum for investigators conducting epidemiological studies (TABLE 1) . The choice of method to assess GFR, either by urinary or plasma clearance, or with one of the available eGFR equations (BOX 2), will therefore undoubtedly affect the reported prevalence of CKD in any given population.
Overcoming false positives
Typically, epidemiological studies that attempt to evaluate the prevalence of CKD only assess the GFR of each participant once at baseline for practical reasons, as taking repeated measurements is time consuming and costly. These 'single-test' studies, however, fail to adhere to the 3 month duration component of the KDIGO guidelines, which is required to confirm a CKD diagnosis 11 . 'One-off ' testing results in a rate of false positives for CKD diagnosis of about 30% for eGFR and is even higher for albuminuria [65] [66] [67] . Of note, repeated GFR testing -although preferable to 'one off ' testing -can also lead to false positives as a result of regression to the mean. False negative results are also an issue for epidemiological studies, especially in younger populations when a fixed GFR threshold of <60 ml/min/1.73 m 2 is used to define CKD, as this value is below the lower limit of normal for a young population 66 . Seminal findings that describe the misclassification of patients in epidemiological studies that have relied on 'one-off ' measurements for determination of GFR are of great importance for establishing the true global burden of CKD. Indeed, any epidemiological study of the prevalence of CKD that employs only a single eGFR or albuminuria determination must be regarded as potentially misleading. Repeated measurements over a defined interval of time after an initial determination of eGFR are necessary to confirm CKD, evaluate the pace of progression and avoid false positive errors 66 . False positives can also arise in other situations. For example, many epidemiological studies do not control for the impact of diet, especially protein intake, on renal function. Chronically low protein intake, prevalent in areas of limited food supply but also common in elderly populations, can lead to a physiologically reduced GFR, on a functional not on a disease basis. Protein intake is a major determinant of true or mGFR in normal individuals. High intake of meat protein can not only increase mGFR but can transiently raise serum creatinine levels and have opposite effects on eGFRcr levels.
The ancestry coefficient in eGFR equation
The ancestry coefficient is an important component of the MDRD and CKD-EPI creatinine-based equations that aides in understanding the prevalence of CKD in ethnically diverse populations. Application of the African American coefficient to the MDRD equation (1.21) and CKD-EPI creatinine-based equation (1.15) 29,48 results in eGFRs that are 21% and 15% higher for the MDRD and CKD-EPI equations, respectively, than calculations without the coefficient. This coefficient has been criticized as being too high when applied to African Americans with normal renal function and to Africans outside the USA [68] [69] [70] [71] . This point is important from an epidemiological perspective as inaccuracies in the ancestry coefficient could have led to inaccurate estimates of CKD prevalence among African Americans. CKD prevalence is lower among African Americans than among white Americans, whereas the prevalence of end-stage renal disease (ESRD) is much higher.
Renal senescence
The gradual deterioration of renal function that is characteristic of most complex lifeforms. Senescence can refer either to cellular senescence or to senescence of the whole organ. Cellular senescence is commonly believed to underlie organ senescence. Anatomically, renal senescence is characterized by global glomerulosclerosis, tubulointerstitial fibrosis and arteriolosclerosis.
This epidemiological paradox between CKD and ESRD prevalence could be explained, in part, by the application of an inappropriate ancestry coefficient 68 . The confusion over ancestry coefficients is exacerbated for individuals of Asian descent due to distinct correction factors being proposed by different researchers, which hinders accurate estimates of the true CKD prevalence among Asian populations 72, 73 . One approach to diminish potential inaccuracies caused by ancestry coefficients would be to use eGFR equations based on cystatin C, which is seemingly not affected by ethnicity -cystatin C-based equations, therefore, do not require an ancestry correction coefficient 74 . Moreover, the impact of ethnicity on the FAS equation is also theoretically low 75 , suggesting that epidemiological studies investigating the prevalence of CKD with cystatin C-based equations or the FAS equation will be of interest going forward, particularly in defining CKD prevalence among different ethnic populations. Another important limitation of all the current eGFR equations is that they include demographic terms, such as ancestry, sex and age. Developments in the past few years, however, suggest that eGFR equations can be developed that do not contain such demographic terms 30, 76 . If successful, then the prospects for developing better estimates of the prevalence of CKD based on consensus eGFR thresholds will be enhanced as interactions with demographic covariates and eGFR will be minimized 77 .
Determining the global burden of CKD CKD represents a major public health issue that can consume substantial financial and social resources. In addition, CKD is a risk factor for hypertension and cardiovascular disease, which together constitute a substantial cause of morbidity and mortality in the general population of most societies 13, 78, 79 . With the view of better understanding the influence of CKD on society, keen interest exists in assessing the burden of the disease across different populations worldwide.
Current estimates of CKD prevalence
Using the widely accepted definitions of CKD advocated by KDOQI 9 and KDIGO 11 , systematic and narrative reviews have estimated the global prevalence of CKD (stages 1-5) to be 3-18% 1,2,4,5,7,12 , with a higher prevalence in females than in males, at least among those aged >40 years at the time of CKD diagnosis, and with a substantial contribution from the elderly population 5 . A comprehensive analysis in 2010 found that the age standardized prevalence of CKD stages 1-5 among adults residing in 32 countries to be 10.4% among men and 11.8% among women (range 4.5-25.7% for men and 4.1-18.4% for women) 5 . The population of these 32 countries accounts for approximately 49% of the adult global population, translating into an estimated global burden of CKD of about 500,000,000 persons. About 236,000,000 (48%) of the these individuals fall into CKD stages 3-5 as defined solely by an eGFR <60 ml/min/1.73 m², and of these individuals, 50% are >60 years of age 5 .
Single country estimations of CKD prevalence vary widely 1, 5, 12, 80 . For instance, a comprehensive survey of 47,204 adults in China found a crude overall prevalence of CKD of 10.8%, but only 15% had CKD 3tage 3-5 and 80% of individuals with CKD eGFR stage 3A had no albuminuria 80 . The reported prevalence of CKD also varies widely between European populations. Investigators of one study reported CKD prevalences of 3.3% in Norway, 17.1% in north-eastern Germany 1 and 5.8% in Poland 12 . Furthermore, a systematic survey found an almost fivefold difference between the CKD prevalence rates of South Korean men (4.5%) and San Salvadoran men (26%) 5 . The heterogeneity in prevalence observed between or even within countries can only be partially explained by differences in the prevalence of CKD risk factors, such as obesity or diabetes 1, 13 . Demographic and socioeconomic factors, which include age and income, genetic susceptibility, rural versus urban residence, prevailing diet, climate, communicable diseases, pollution and environmental toxins might all contribute in varying degrees to the observed global variations in prevalence of CKD 13, 81 .
The influence of age
The prevalence of CKD, as defined by KDOQI and KDIGO criteria, rises substantially with age, and estimates of CKD prevalence depend on the method used to measure or estimate GFR 2,7,78 (TABLES 1,2). Moreover, physiologic decreases in kidney function occur with age 82 . Epidemiologic studies, particularly those that use 'one-off ' testing of a biomarker to define GFR, tend to capture many elderly individuals with a normal age-related decline in eGFR, and are therefore likely to overestimate the burden of CKD, especially in an aged population 82, 83 . Whether the selection of a single, absolute threshold for eGFR or mGFR for identification of CKD (for example, <60 ml/min/1.73 m², which has been applied even in the absence of markers of kidney damage), has led to over-estimation of CKD prevalence in elderly populations exhibiting a normal 'physiologic' decline in GFR with ageing (renal senescence) remains highly controversial 78, 82, 84 . This controversy raises philosophical issues as to what is disease and what is normal ageing that are not easily resolved.
Thus, using current guideline-based approaches, the overall prevalence of CKD in any given community is notably influenced by the age distribution of the population and by the specific eGFR equation used. Values for CKD prevalence vary from 16% to >90% among individuals >70 years of age; further work is required to resolve the discrepancies in estimates of CKD prevalence among the elderly based on measured plasma iohexol clearance and eGFR calculations. Age-sensitive alterations in the thresholds to define CKD according to eGFR values, such as reducing the threshold to <45 ml/min/1.73 m 2 for patients older than 65 years, have been suggested as a way to deal with these issues 82, 83 ; however, this approach has proven to be highly controversial 84 and possibly difficult to implement.
By contrast, systematic underestimation of CKD can also occur in analyses of younger age groups, when a single eGFR threshold of <60 ml/min/1.73 m² is used
Disability-adjusted life years
A measure of overall disease burden, expressed as the number of years lost owing to ill-health, disability or early death.
Generic CKD
A classification of chronic kidney disease (CKD) in which a definite cause is not identified or in which all causes (known or unknown) are included.
as the sole criterion for CKD 66, 85 . Quantitatively, however, young populations are much less likely to have CKD than older populations, and thus misclassification of CKD in individuals <40 years of age is likely to contribute minimally to overall errors in determining CKD prevalence. According to population-based surveys the prevalence of CKD in the USA has increased ~2% per year in the periods between 1988-1994 and 2005-2010 . This reported increase was only identified using certain eGFR equations and occurred predominantly among individuals >65 years of age, notably in the absence of any increase in the prevalence of albuminuria 86 . A 2016 study, however, showed that the population prevalence of CKD using eGFR values in the USA has remained fairly constant since 2004 (REF. 87 ). Due to issues concerning the definitions of CKD in the elderly employing eGFR values, as discussed above, one should view reports showing an increase in CKD prevalence in populations experiencing rapid ageing demographics with some degree of caution.
Interestingly, in the USA the incidence of newlytreated ESRD has tended to be stable or decline (on a year by year basis) since about 2002, especially in the >65-year-old age group 88 . This emerging stability in the incidence rate of treated ESRD has been seen for nearly all aetiologies of CKD, including diabetes mellitus, hypertension and glomerulonephritis, but not in ESRD resulting from autosomal dominant polycystic kidney disease This slight increase in the prevalence of treated ESRD in a period of stable or declining incidence of newly treated ESRD is best explained by low mortality of patients on ESRD treatment. Once a nadir of mortality on ESRD treatment is reached in the face of unchanging incidence rates, the prevalence of treated ESRD might be expected to fall, as mortality on treatment exceeds the intake of newly treated patients. This conjecture seems likely unless the incidence rate of newly treated ESRD rises again, back to values observed in the 1980s and 1990s. Such an increase seems improbable, given the notable decrease in the incidence of newly diagnosed diabetes mellitus (a major cause of renal failure) in the USA since about 2009 (REF. 89 ) and, as mentioned above, the prevalence rates for CKD seem to be stable, at least in the USA 87 . Of note, the prevalence of CKD in the USA is higher in females but males have a higher prevalence of newly treated ESRD 5, 8 . The origins of this apparent sex paradox are uncertain, but are likely multifactorial. The possibility exists that over-diagnosis of CKD is more marked in elderly women than in men. Women on average have lower eGFR and mGFR (uncorrected for body surface area) and they tend to develop a GFR value of <60 ml/min/1.73 m 2 at an earlier age than men. This physiological sex difference in GFR might contribute to greater overdiagnosis of CKD in women and men as they age, particularly in the absence of abnormal albuminuria.
The Global Burden of Disease study A unique perspective on the global burden of CKD is provided by the Global Burden of Disease (GBD) collaboration, who have undertaken the monumental task of cataloguing the worldwide epidemiology and burden of communicable and non-communicable diseases since 1990 (REF. 90 ). The researchers involved in this effort catalogued over 300 diseases, including CKD, in 188 countries from 1990 to 2013. Whether the coding system used by the GBD investigators to identify CKD overlaps with the KDOQI or KDIGO systems is unclear, but categorization of CKD required a sustained diagnosis of CKD for >3 months, as specified by KDIGO. The degree to which estimates of CKD provided by the GBD collaboration parallel with estimates with more renal-focused studies is also unclear; nevertheless, this large-scale study provides some useful insights into the global prevalence of CKD. For their analysis, the GBD investigators divided cases of CKD into four categories: those associated with or caused by diabetes mellitus, those associated with or caused by hypertension, those caused by glomerulonephritis and those resulting from other causes (polycystic kidney disease or congenital abnormalities of the kidney and urinary tract). Crude and age-standardized overall CKD prevalence rates, disability-adjusted life years (DALY) experienced, years lived with disability, years lost to premature mortality and health life expectancy for communicable and non-communicable diseases, including CKD, were examined for each country 91 . During the 23 year study, the prevalence of CKD increased by 48%, from 318,665,000 to 471,916,000 cases (about 2.1% per year), which is as expected given the population growth over this time (TABLE 3) . However, the overall age-standardized prevalence rate (per 100,000 adults) of all-cause generic CKD declined by 3.6% between 1990 and 2013 from a prevalence of 7,237 cases per 100,000 people in 1990 to 6,973 cases per 100,000 people in 2013. The GBD investigators also noted a >10% decline in the prevalence of CKD associated with hypertension and glomerulonephritis, whereas CKD associated with diabetes mellitus increased by almost 12% and CKD resulting from other causes increased by 3%. While the incidence of newly diagnosed type 2 diabetes mellitus has been decreasing in many developed countries (including the USA) it has been increasing in developing countries, largely under the influence of obesity. In 2013, CKD resulting from other causes accounted for almost 37% of cases of CKD, whereas CKD associated with diabetes mellitus, hypertension and glomerulonephritis accounted for 19%, 21% and 23% of all CKD cases, respectively. Assessments of DALY, a measure of overall disease burden expressed as the number of years lost due to disability or early death, showed a decrease in the burden associated with glomerulonephritis-induced CKD from 1990 to 2013 but an increase in DALY for CKD associated with diabetes mellitus, hypertension and other causes. CKD was ranked among the top ten diseases that severely impact DALY in 27 of the 188 countries examined. Further, 14 of these 27 countries (52%) were in South or Central America and three of the four countries in which CKD was in the top five tier of DALY were in Central America (Mexico, El Salvador and Nicaragua) 91 . Many studies have documented poor awareness of the presence of CKD among individuals 92 . The GBD has updated data through 2015 for the global prevalence of CKD 93 (see Supplementary information S1 and S2 (table)). For the 2015 GBD data, investigators divided CKD into stages (3, 4, 5 untreated by dialysis and ESRD). These data suggest a continuing stable or declining prevalence of non-dialysis-dependent CKD in many, but not all, countries worldwide, and a decline in ESRD 93 . The aggregate epidemiologic data strongly suggest that all-cause generic CKD is a common disorder that is distributed nonuniformly among the global population, and that hot spots exist, both between and within regions of countries. Such a phenomenon deserves close scrutiny as it could aid in the identification of aetiological factors that are susceptible to preventive strategies. When examined as a whole, however, the epidemiological data show that we are not currently in the midst of a global CKD epidemic, as has been previously suggested. The continuing rise in global prevalence of treated ESRD might be a phenomenon that is more closely linked to improved access to care rather than to a secular change of CKD itself. The data do, however, provide possible explanations for the reported variations in CKD prevalence and the consequence of CKD on disability. Although immensely important, the GBD data is weakened in its inability to consistently 'stage' CKD according to the KDIGO guidelines due to the sheer size of the study. The GBD data also cannot be used to reliably evaluate the accuracy of the specific eGFR formula used or assess albuminuria if CKD is identified. A more detailed country-specific and subregion evaluation, which includes assessment of duration of CKD, ancestry, nephron endowment at birth, the genetics of progressive CKD and prevailing diet, climate and nephrotoxin exposure is needed to further explore the nuances identified by the GBD study 13 . The impact of greater awareness of CKD by physicians (leading to more testing of eGFR or albuminuria) and increased coding of CKD and its stages in medical records must be considered when evaluating changes in reported global CKD prevalence. Furthermore, ascertainment bias can operate when populations are self-selected for inclusion in prevalence surveys. Individuals might volunteer for screening programs designed to identify CKD when they have concerns about kidney disease or have relatives with CKD. Such biases can influence reports of prevalence of CKD applicable to the general population. These biases can add to considerations of age and ancestry on CKD diagnosis and staging. Nephron endowment at birth, which is currently only estimated by birth weight, and its contribution to the rate of decline in GFR with normal ageing might also warrant consideration for its effects on CKD staging and future risk of CKD 94, 95 , although, such parameters would be difficult to assess in large epidemiologic studies.
Conclusions
This Review of issues relating to the interpretation of studies of CKD prevalence raises questions that challenge the existence of a global epidemic of CKD. The pitfalls that exist in translating available epidemiological data hinder accurate assessment of the global burden of CKD. These pitfalls include issues in the accuracy of formulas to estimate GFR, including issues with biomarker calibration, the choice of biomarker and equation, and the influence of non-GFR determinants on biomarker levels; issues relating to the presence of false positives, particularly with single-test studies; issues relating to our understanding and application of ancestry coefficients to eGFR equations; lack of a disease duration component or assessment of albuminuria in population studies; and ascertainment bias in nonrandom selections of survey participants. Based on the arguments presented here, one might take the view that we are currently unable to fully know the global prevalence of generic CKD to any meaningful degree of precision. Alternatively, one could posit that many studies have overestimated the burden of CKD and its rate of change in the general population. The cumulative impact of pitfalls in prevalence estimates could mean that the global prevalence of CKD has been overestimated by >50% 82 . A focus on the origins of the variation of CKD prevalence within regions and between countries could be a rewarding approach to determine the epidemiology of CKD on a global basis. We believe that advances in the testing methodology for identification and classification of CKD will improve our ability to better understand this all too common disorder. However, advances in testing methods can only do so much -nephrologists and epidemiologists need to ensure that data generated from future epidemiological studies investigating the burden of CKD in defined populations are reliable. Investigators can improve the reliability of data by controlling for some of the errors that are commonly encountered when defining CKD and avoid universally applying criteria for CKD diagnosis across all segments of a given population.
